Winston De La Haye
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Dr. Sloshower presents results from a psilocybin-assisted therapy study for major depression, showing larger antidepressant effects than placebo, with lasting mood improvements. Dr. Kilpatrick discusses longitudinal case studies.
Jordan Sloshower, Stephanie Kilpatrick
Panel explores interplay between psychedelics and Buddhist philosophy/practice, discussing potential for expanded awareness/self-discovery/liberation and presenting unique perspective on relationship between the two.
Daan Keiman, Kan Yan
Psychedelic drugs may enhance creative thinking and empathy, supported by anecdotal reports and some scientific evidence. Studies show time- and construct-dependent effects on flexible cognition, with brain imaging linking changes
Natasha Mason
Psilocybin's therapeutic potential for mental health is being studied for its mechanisms and optimal therapeutic window. Research investigates brain changes during and after psilocybin experiences in healthy volunteers.
Jessica L Nielson
Roland R. Griffiths, PhD, honored at Psychedelic Science Conference. Pioneered psilocybin research, founded Johns Hopkins Center for Psychedelic and Consciousness Research, influencing a new wave of researchers.
William Richards, Theresa Carbonaro, Katherine Bonson
Panel discusses LGBT+ perspectives on psychedelic therapy, emphasizing community's healing role. Recommendations for queer-inclusive therapy and research draw from queer history, including AIDS crisis and conversion therapy.
Alex Belser, Clancy Cavnar
Robin Carhart-Harris, Head of Centre for Psychedelic Research at Imperial College London, conducted pioneering clinical studies with psilocybin and other psychedelic drugs for over 40 years. He collaborates with Professor
Indigenous cultures use psychedelics in group settings, contrasting with recent individual-focused psychedelic therapy research. New studies explore group administration for cost-effective care and conventional therapy benefits.
Paul Thambi, Christopher “Chris” Stauffer
Roland Griffiths, Ph.D., from Johns Hopkins University, leads research on psilocybin's effects, including therapeutic studies for psychological distress, depression, addiction, and brain imaging for neural mechanisms.
Roland Griffiths
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.